Baybis M, Yu J, Lee A, Golden JA, Weiner H, McKhann II G et al.. mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann Neurol 56: 478-487

The Children's Hospital of Philadelphia, Filadelfia, Pennsylvania, United States
Annals of Neurology (Impact Factor: 9.98). 10/2004; 56(4):478-87. DOI: 10.1002/ana.20211
Source: PubMed


Balloon cells (BCs) in focal cortical dysplasia (FCD) and giant cells (GCs) in tubers of the tuberous sclerosis complex (TSC) share phenotypic similarities. TSC1 or TSC2 gene mutations in TSC lead to mTOR pathway activation and p70S6kinase (phospho-S6K) and ribosomal S6 (phospho-S6) protein phosphorylation. Phospho-S6K, phospho-S6, and phospho-S6K-activated proteins phospho-STAT3 and phospho-4EBP1 were detected immunohistochemically in GCs, whereas only phospho-S6 was observed in BCs. Expression of four candidate gene families (cell signaling, cell adhesion, growth factor/receptor, and transcription factor mRNAs) was assayed in single, microdissected phospho-S6-immunolabeled BCs and GCs as a strategy to define whether BCs and GCs exhibit differential transcriptional profiles. Among 60 genes, differential expression of 24 mRNAs distinguished BCs from GCs and only 4 genes showed similar expression profiles between BCs and GCs. Tuberin mRNA levels were reduced in GCs from TSC patients with TSC2 gene mutations but were unchanged in BCs. Phospho-S6K, -S6, -STAT3, and -4EBP1 expression in GCs reflects loss of hamartin-tuberin-mediated mTOR pathway inhibition. Phospho-S6 expression alone in BCs does not support mTOR cascade activation in FCD. Differential gene expression profiles in BCs and GCs supports the hypothesis that these cell types derive by distinct pathogenic mechanisms.

8 Reads
  • Source
    • "The mTOR pathway has received attention as a potential mediator of epilepsy since the connection between TSC and mTOR was made about a decade ago. It was initially recognized that mTOR is hyperactive in cells from cortical tubers and focal cortical dysplasias (Baybis et al., 2004; Miyata et al., 2004). More recently, several groups identified de novo somatic mutations of PI3K, AKT3, or mTOR genes in hemimegalencephaly , a condition associated with severe seizures (Lee et al., 2012; Poduri et al., 2012; Riviè re et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The mechanistic target of rapamycin (mTOR) signaling pathway is a crucial cellular signaling hub that, like the nervous system itself, integrates internal and external cues to elicit critical outputs including growth control, protein synthesis, gene expression, and metabolic balance. The importance of mTOR signaling to brain function is underscored by the myriad disorders in which mTOR pathway dysfunction is implicated, such as autism, epilepsy, and neurodegenerative disorders. Pharmacological manipulation of mTOR signaling holds therapeutic promise and has entered clinical trials for several disorders. Here, we review the functions of mTOR signaling in the normal and pathological brain, highlighting ongoing efforts to translate our understanding of cellular physiology into direct medical benefit for neurological disorders.
    Neuron 10/2014; 84(2):275-291. DOI:10.1016/j.neuron.2014.09.034 · 15.05 Impact Factor
  • Source
    • "This is the first report of mTOR mutation in neurological disease so that the validation of activity is awaited. Dysmorphic cells in the brain of focal cortical dysplasia type IIB patient showed hyper-phosphorylation of S6 (Baybis et al., 2004; Miyata et al., 2004). Although genetic analysis forthcoming, it is likely that there may be somatic mutations of unknown genes in mTORC1 signaling pathways that are responsible for cellular abnormality in focal cortical dysplasia. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Target of rapamycin (TOR) was first identified in yeast as a target molecule of rapamycin, an anti-fugal and immunosuppressant macrolide compound. In mammals, its orthologue is called mammalian TOR (mTOR). mTOR is a serine/threonine kinase that converges different extracellular stimuli, such as nutrients and growth factors, and diverges into several biochemical reactions, including translation, autophagy, transcription, and lipid synthesis among others. These biochemical reactions govern cell growth and cause cells to attain an anabolic state. Thus, the disruption of mTOR signaling is implicated in a wide array of diseases such as cancer, diabetes, and obesity. In the central nervous system, the mTOR signaling cascade is activated by nutrients, neurotrophic factors, and neurotransmitters that enhances protein (and possibly lipid) synthesis and suppresses autophagy. These processes contribute to normal neuronal growth by promoting their differentiation, neurite elongation and branching, and synaptic formation during development. Therefore, disruption of mTOR signaling may cause neuronal degeneration and abnormal neural development. While reduced mTOR signaling is associated with neurodegeneration, excess activation of mTOR signaling causes abnormal development of neurons and glia, leading to brain malformation. In this review, we first introduce the current state of molecular knowledge of mTOR complexes and signaling in general. We then describe mTOR activation in neurons, which leads to translational enhancement, and finally discuss the link between mTOR and normal/abnormal neuronal growth during development.
    Frontiers in Molecular Neuroscience 04/2014; 7(1):28. DOI:10.3389/fnmol.2014.00028 · 4.08 Impact Factor
  • Source
    • "Occasionally tubers become cystic and even calcified (Rott et al., 2002). Since the TSC1/TSC2 complex negatively regulates mTOR activity (Baybis et al., 2004; Crino, 2004; Tee et al., 2002), the enlarged neurons of cortical tubers have high mTOR activity as measured by increased ribosomal protein S6 phosphorylation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tuberous sclerosis complex (TSC) is an autosomal dominant monogenetic disorder that is characterized by the formation of benign tumors in several organs as well as brain malformations and neuronal defects. TSC is caused by inactivating mutations in one of two genes, TSC1 and TSC2, resulting in increased activity of the mammalian Target of Rapamycin (mTOR). Here, we explore the cytoarchitectural and functional CNS aberrations that may account for the neurological presentations of TSC, notably seizures, hydrocephalus, and cognitive and psychological impairments. In particular, recent mouse models of brain lesions are presented with an emphasis on using electroporation to allow the generation of discrete lesions resulting from loss of heterozygosity during perinatal development. Cortical lesions are thought to contribute to epileptogenesis and worsening of cognitive defects. However, it has recently been suggested that being born with a mutant allele without loss of heterozygosity and associated cortical lesions is sufficient to generate cognitive and neuropsychiatric problems. We will thus discuss the function of mTOR hyperactivity on neuronal circuit formation and the potential consequences of being born heterozygote on neuronal function and the biochemistry of synaptic plasticity, the cellular substrate of learning and memory. Ultimately, a major goal of TSC research is to identify the cellular and molecular mechanisms downstream of mTOR underlying the neurological manifestations observed in TSC patients and identify novel therapeutic targets to prevent the formation of brain lesions and restore neuronal function.
    International journal of developmental neuroscience: the official journal of the International Society for Developmental Neuroscience 02/2013; 31(7). DOI:10.1016/j.ijdevneu.2013.02.008 · 2.58 Impact Factor
Show more